Publications
Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? Vrije Universiteit Brussel
AIM: To assess the efficacy and safety of ranibizumab in the treatment of choroidal neovascularisation (CNV) caused by pathologic myopia (PM).
DESIGN: Prospective, multicentre, interventional case series.
METHODS: 40 eyes of 39 consecutive patients with PM and CNV were treated with 'on demand' intravitreal injection of ranibizumab 0.5 mg. Final best corrected visual acuity (BCVA) and its change from baseline were the main outcome ...
Iris atrophy and erosion caused by an anterior-chamber angle-supported phakic intraocular lens Vrije Universiteit Brussel University of Antwerp
UNLABELLED: We report a case in which an angle-supported phakic IOL was implanted to correct high myopia. Subsequently, the patient experienced photophobia, glare, halo, and loss of visual acuity and became concerned about the cosmetically deforming aspect of her eye. Findings included endothelial cell loss, cataract, pupil ovalization, and severe iris atrophy. The pIOL was removed and cataract surgery was performed, followed by implantation ...
A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV Vrije Universiteit Brussel
AIMS: The aim was to compare the efficacy of intravitreal therapy with bevacizumab and ranibizumab for choroidal neovascularization (CNV) in pathologic myopia (PM).
METHODS: This was a prospective multicenter randomized nonblinded trial.
RESULTS: In seven centers, 78 eyes were randomized 1:1 to treatment with bevacizumab (group B, 40 eyes) or ranibizumab (group R, 38 eyes) given with an "on demand" regimen (PRN). The mean ...